PPMD Community

John D. Porter, PhD
  • Male
  • Gaithersburg, MD
  • United States
Share on Facebook
Share

John D. Porter, PhD's Friends

  • Deb Robins
 

John D. Porter, PhD

Latest Activity

John D. Porter, PhD posted a blog post

A New Dog Model for Drug Development in Duchenne

Photograph: Chris Kench/www.chriskenchphotography.com via The GuardianSome…See More
Dec 21, 2015
0 Comments
John D. Porter, PhD posted a blog post

Dystrophin Mutations Affect Not Only Existing Muscle Fibers, but Satellite Cells As Well

A recent paper by Michael Rudnicki’s group at Ottawa Hospital Research Institute and the University of Ottawa has provided new insights into what we view as the critical targets for therapies in Duchenne (Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division. Dumont et al., Nature Medicine…See More
Dec 17, 2015
0 Comments
John D. Porter, PhD commented on John D. Porter, PhD's blog post A Paradigm Shift in Drug Discovery
"Thanks Deb.  I'm very happy to get your feedback.  There does have to be a paradigm shift in our field, where clinical data (natural history or from trials) is not silo'ed but shared.  Individual studies can provide limited…"
Oct 30, 2015
Deb Robins commented on John D. Porter, PhD's blog post A Paradigm Shift in Drug Discovery
"JP, that's an insightful analogy for advancement, you picked up on. We're going to need to collect so much more data to make such algorithms simulate the effect of experimental drugs credibly and/or dosages. There are so many variables in…"
Oct 29, 2015
Jason Darienzo commented on John D. Porter, PhD's blog post A Paradigm Shift in Drug Discovery
"http://www.ted.com/talks/jay_bradner_open_source_cancer_research"
Oct 27, 2015
Jason Darienzo commented on John D. Porter, PhD's blog post A Paradigm Shift in Drug Discovery
"TED Talk's on Drug Discovery and…"
Oct 27, 2015
John D. Porter, PhD posted a blog post

A Paradigm Shift in Drug Discovery

Last week I participated in a briefing for Congressional staff in honor of the 10th anniversary of the founding of the Critical Path Institute, our partner in the…See More
Oct 27, 2015
4 Comments
John D. Porter, PhD posted blog posts
Oct 16, 2015
John D. Porter, PhD posted a blog post

The Power is in Your Hands: Duchenne Regulatory Science Consortium

About a month ago, I wrote to you to announce the launch of a new partnership between PPMD and the Critical Path Institute (C-Path) called the Duchenne Regulatory Sciences Consortium or D-RSC (see “…See More
Sep 16, 2015
0 Comments
John D. Porter, PhD's blog post was featured

Different Together: PPMD Announces the Duchenne Regulatory Science Consortium

Signal to NoiseThis is a measure used in science and engineering to compare the level of a desired signal (a measured outcome) to the background noise. In a way, this is the question of what information carries weight/is meaningful and what information clouds the issue.While this sounds really complicated, we have witnessed the interaction of signal and noise first-hand in discussions around natural history of Duchenne and when…See More
Aug 3, 2015
0 Comments
John D. Porter, PhD posted a blog post

Different Together: PPMD Announces the Duchenne Regulatory Science Consortium

Signal to NoiseThis is a measure used in science and engineering to compare the level of a desired signal (a measured outcome) to the background noise. In a way, this is the question of what information carries weight/is meaningful and what information clouds the issue.While this sounds really complicated, we have witnessed the interaction of signal and noise first-hand in discussions around natural history of Duchenne and when…See More
Aug 3, 2015
0 Comments
Rachel Sedacca-Replogle favorited John D. Porter, PhD's blog post Santhera Releases Positive Data from Phase III Clinical Trial of Idebenone (Raxone®/Catena®) in Duchenne
May 8, 2015
John D. Porter, PhD posted a blog post

Let's Get Them Moving Workshop: Our First Steps Toward That Goal

Yesterday, Parent Project Muscular Dystrophy and Duchenne Parent Project-Netherlands (DPP) co-hosted the first ever conference on assistive technology for Duchenne muscular dystrophy. There were twenty-five participants in the workshop, from six countries, representing academia (both researchers and engineers), companies, clinical practice, and patient advocacy. PPMD was represented by Pat Furlong, Annie Kennedy, and myself. Elizabeth Vroom (DPP-Netherlands) set the tone for the meeting with…See More
Apr 28, 2015
0 Comments
John D. Porter, PhD posted a blog post

Santhera Releases Positive Data from Phase III Clinical Trial of Idebenone (Raxone®/Catena®) in Duchenne

Today, Santhera has published the results in the highly prestigious journal, The Lancet, from their successful clinical trial of Raxone®/Catena® . They will present these results later this week, at the annual meeting of the American Academy of Neurology. First, idebenone was safe and well tolerated. Importantly, treatment of study subjects, age 10-18, for one year…See More
Apr 21, 2015
0 Comments
David commented on John D. Porter, PhD's blog post Recapping the FDA-NIH Dystrophin Methodology Workshop
"Here here Richard! We all want rigor in our methods but this is beyond absurd. Let's go already!!!"
Mar 29, 2015
Shelly commented on John D. Porter, PhD's blog post Recapping the FDA-NIH Dystrophin Methodology Workshop
"All the beseeching eyes of all the parents globally are on FDA'S APPROVAL OF ETEPLIRSEN . The only hope for dmd community is approval of one such drug which is gonna affect the processing of.other potential drugs amenable to other deletions…"
Mar 28, 2015

Profile Information

About me:
Chief Executive Officer

After conducting research in my own laboratory in academia for over 20 years, and then facilitating the funding of neuromuscular disease research by National Institute of Neurological Disorders and Stroke (NINDS) for the next 10 years, PPMD offered me this unparalleled opportunity to synthesize that experience and bring it directly to bear on the challenges of better quality of life and novel treatments for people with Duchenne. I’m thrilled to join such a strong and vibrant team at PPMD, and work with the broader community of dedicated scientists, physicians, patient advocates, and families, in a leave no-stone-unturned approach to end Duchenne.
City:
Washington, DC

John D. Porter, PhD's Blog

A New Dog Model for Drug Development in Duchenne

Posted on December 21, 2015 at 11:03am 0 Comments

Photograph: Chris Kench/www.chriskenchphotography.com via The Guardian

Some…

Continue

Dystrophin Mutations Affect Not Only Existing Muscle Fibers, but Satellite Cells As Well

Posted on December 17, 2015 at 4:00pm 0 Comments

A recent paper by Michael Rudnicki’s group at Ottawa Hospital Research Institute and the University of Ottawa has provided new insights into what we view as the critical targets for therapies in Duchenne (Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division.…

Continue

A Paradigm Shift in Drug Discovery

Posted on October 27, 2015 at 10:50am 4 Comments

Last week I participated in a briefing for Congressional staff in honor of the 10th anniversary of the founding of the Critical Path Institute, our partner in the…

Continue

Annual Meeting: Patient-Centered Outcomes Research Institute (PCORI)

Posted on October 16, 2015 at 1:07pm 0 Comments

The first annual meeting of PCORI was held in Washington, DC on October 6-8.  1,100 researchers, patients, caregivers, health system and industry representatives, and others were present to hear updates on patient-centered comparative clinical effectiveness research.  PCORnet is a “network of…

Continue

Comment Wall

You need to be a member of PPMD Community to add comments!

Join PPMD Community

  • No comments yet!
 
 
 

Need help using this community site? Visit Ning's Help Page.

Members

Events

July 2017
SMTWTFS
1
2345678
9101112131415
16171819202122
23242526272829
3031

© 2017   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service